China Galaxy Securities: From hematologic tumors to solid tumors, TCE enters a fast track of development.

date
10:48 17/11/2026
avatar
GMT Eight
TCE has achieved commercialization, with multiple products approved for hematologic tumors, randomized OS confirmed in SCLC, and MM moving into earlier-line treatment.
China Galaxy Securities released a research report stating that, following bispecific antibodies and ADCs, TCEs are becoming a new hotspot for deals in the innovative drug sector. China has become an important source of global TCE innovation. As of mid-2026, Chinese pharmaceutical companies had cumulatively advanced more than 10 TCE projects into overseas markets, covering trispecific TCEs, masked TCEs, 2+1 structures, and others. TCEs have achieved commercialization, with multiple products approved for hematologic tumors, randomized OS confirmation already available in SCLC, and MM moving into earlier-line treatment. It is recommended to watch targets related to solid tumors, hematologic tumors, and autoimmune diseases. The main views of China Galaxy Securities are as follows: Deals related to innovative TCE drugs are surging, and TCEs are expected to become a new cradle for blockbuster drugs Following bispecific antibodies and ADCs, TCEs are becoming a new hotspot for deals in the innovative drug sector. As the track continues to heat up, BD competition around high-quality TCE assets has clearly accelerated. In 2025 alone, 10 Chinese pharmaceutical companies advanced TCE projects into overseas markets, with cumulative potential deal value exceeding US$7 billion. On September 1, 2026, Simcere Zaiming and Roche reached a global exclusive licensing agreement for the CD79a/CD19/CD3 trispecific antibody SIM0660, under which Simcere Zaiming will receive a US$75 million upfront payment, with the total deal value reaching up to US$1.53 billion. SIM0660 is currently still in the preclinical stage. On October 2, Abogen Biosciences reached an agreement with Novartis, granting Novartis global exclusive licensing rights to ABO2203 (an mRNA-encoded CD19/CD3 TCE pipeline), as well as an exclusive licensing option to develop other potential projects based on its proprietary RNA platform, with a US$575 million upfront payment and a total deal value of up to US$7.775 billion. The TCE indication landscape continues to expand: hematologic tumors as the foundation, solid tumors breaking through, and autoimmune diseases taking the baton TCEs have completed both technical and commercial validation in hematologic tumors, with targets concentrated on CD19/CD20 and BCMA/GPRC5D, and indications gradually advancing toward earlier lines. In 2025, the overall survival benefit from the randomized Phase III trial of Tarlatamab advanced TCE treatment of solid tumors to clinical validation; multiple TCEs globally are now being developed for lung cancer, neuroendocrine cancer, prostate cancer, and others. In addition, by targeting CD19/CD20/BCMA, TCEs can deeply deplete autoreactive B cells/plasma cells and achieve immune reset, which is expected to fundamentally change the treatment paradigm for autoimmune diseases such as SLE and RA; however, this is still in the exploratory stage, and no product has yet been approved. China's strength: the rise of TCE platform companies and the wave of internationalization China has become an important source of global TCE innovation. As of mid-2026, Chinese pharmaceutical companies had cumulatively advanced more than 10 TCE projects into overseas markets, covering trispecific TCEs, masked TCEs, 2+1 structures, and others. Zelgen Biopharmaceuticals, Leads Biolabs, and Antengene are important representative companies in the TCE field. In addition, INNOVENT BIO (IBI3003 BCMA/GPRC5D/CD3 Phase III), Keymed Biosciences (CM336 licensed to Gilead, total value US$2.175 billion), Visirna Therapeutics (GR1803 licensed to Cullinan, total value US$712 million), and Harbour BioMed (HBM7022 licensed to AZ; HBM7020 licensed to Otsuka, total value US$670 million) all occupy important positions. Risk warnings: 1. Increased macroeconomic pressure leading to insufficient pharmaceutical consumption; 2. Reimbursement for innovative drugs falling short of expectations; 3. Global order transfer brought about by geopolitics; 4. Centralized procurement or fee/price cuts exceeding market expectations.